Search

Your search keyword '"Majer, I."' showing total 314 results

Search Constraints

Start Over You searched for: Author "Majer, I." Remove constraint Author: "Majer, I."
314 results on '"Majer, I."'

Search Results

1. Event Generators for High-Energy Physics Experiments

2. Transverse momentum distributions in low-mass Drell-Yan lepton pair production at NNLO QCD

3. $VH+\text{jet}$ production in hadron-hadron collisions up to order $\alpha_s^3$ in perturbative QCD

4. Precise predictions for $\mathrm{WH}$+jet production at the LHC

5. Predictions for $\mathrm{Z}$-boson production in association with a $\mathrm{b}$-jet at $\mathcal{O}(\alpha_s^3)$

6. Associated production of a Higgs boson decaying into bottom quarks and a weak vector boson decaying leptonically at NNLO in QCD

7. Event generators for high-energy physics experiments

8. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

9. Event generators for high-energy physics experiments

12. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

14. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

15. 75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

16. 1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6

19. VH + jet production in hadron-hadron collisions up to order <math> <msubsup> <mi>α</mi> <mi>s</mi> <mn>3</mn> </msubsup> </math> $$ {\alpha}_{\mathrm{s}}^3 $$ in perturbative QCD

20. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

21. Transverse momentum distributions in low-mass Drell-Yan lepton pair production at NNLO QCD

22. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

26. V H + jet production in hadron-hadron collisions up to order α3s in perturbative QCD

27. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

28. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

30. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

32. Transverse momentum distributions in low-mass Drell-Yan lepton pair production at NNLO QCD

33. Precise predictions for WH+jet production at the LHC

34. Predictions for <math><mi>Z</mi></math>-Boson Production in Association with a <math><mi>b</mi></math>-Jet at <math><mrow><mi>O</mi><mo>(</mo><msubsup><mrow><mi>α</mi></mrow><mrow><mi>s</mi></mrow><mrow><mn>3</mn></mrow></msubsup><mo>)</mo></mrow></math>

35. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States

36. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

37. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

38. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

41. High mobility group box 1 protein in bronchoalveolar lavage fluid and correlation with other inflammatory markers in pulmonary diseases

43. TREM-1 and TREM-2 Expression on CD14+ Cells in Bronchoalveolar Lavage Fluid in Pulmonary Sarcoidosis and Hypersensitivity Pneumonitis in the Context of T Cell Immune Response

44. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

45. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

46. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

48. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

49. Adherence to treatment in allergic rhinitis using mobile technology : The MASK Study

50. Associated production of a Higgs boson decaying into bottom quarks and a weak vector boson decaying leptonically at NNLO in QCD

Catalog

Books, media, physical & digital resources